Table 2.
Diagnostic performance of a single baseline hs-cTnT below the limit of quantitation of 6 ng/L for acute myocardial injury (defined as any hs-cTnT increase above the sex-specific 99th percentiles within 24-hours of presentation) in patients with a baseline hs-cTnT<6 ng/L with serial measurements in the CV Data Mart Biomarker Cohort. LoQ: limit of quantitation.
| CV Data Mart Biomarker Cohort | Baseline hs-cTnT<6 ng/L (LoQ) with serial hs-cTnT measurements | |||||
|---|---|---|---|---|---|---|
| All-comers | Chest Pain Subgroup | |||||
| All | Men | Women | All | Men | Women | |
| Patients with baseline hs-cTnT<6 ng/L (LoQ) and serial measurements, n (%) | 11962 | 4264 | 7698 | 5840 | 2219 | 3621 |
| Patients with baseline hs-cTnT<6 ng/L with 2h hs-cTnT<6 ng/L (LoQ), n (%) | 10184 (85) | 3469 (81) | 6715 (87) | 5085 (87) | 1865 (84) | 3220 (89) |
| Negative predictive value of hs-cTnT<6 ng/L for acute myocardial injury (hs-cTnT>99th percentile), % (95% CI) | 98.8 (98.6, 99.0) |
99.3 (99.0, 99.6) |
98.5 (98.2, 98.7) |
98.9 (98.6, 99.1) |
99.4 (99.0, 99.7) |
98.6 (98.1, 98.9) |
| Sensitivity of hs-cTnT<6 ng/L for acute myocardial injury (hs-cTnT>99th percentile), % (95% CI) | 99.6 (99.5, 99.6) |
99.8 (99.8, 99.9) |
99.3 (99.1, 99.4) |
99.0 (98.8, 99.2) |
99.6 (99.4, 99.8) |
98.4 (97.9, 98.8) |
| Acute myocardial injury (hs-cTnT >99th percentile) among patients with a baseline hs-cTnT<6 ng/L (LoQ), % | 1.2% (146/11962) | 0.7% (29/4264) | 1.5% (117/7698) | 1.1% (65/5840) | 0.6% (13/2219) | 1.4% (52/3621) |
| Maximum hs-cTnT concentrations in those with acute myocardial injury (ng/L) (median and Q1, Q3) | 20 (14, 43) | 40 (21, 71) | 16 (13, 33) | 25 (14, 48) | 40 (24, 70) | 21 (14, 47) |